There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novavax (NVAX) and Hookipa Pharma (HOOK) with bullish sentiments.
Novavax (NVAX)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Novavax, with a price target of $207.00. The company’s shares closed last Monday at $139.50.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 31.3% and a 37.8% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Achieve Life Sciences, and Miragen Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Novavax with a $179.00 average price target, implying a 50.1% upside from current levels. In a report released yesterday, B.Riley Financial also maintained a Buy rating on the stock with a $223.00 price target.
See today’s analyst top recommended stocks >>
Hookipa Pharma (HOOK)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Hookipa Pharma today and set a price target of $16.00. The company’s shares closed last Monday at $11.60.
According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 12.2% and a 43.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Trillium Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hookipa Pharma with a $18.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.